Skip to main
CRMD
CRMD logo

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. is poised for long-term growth driven by its innovative product DefenCath, which is gaining traction in the infection prevention market, particularly within U.S. dialysis centers. The company has secured multiple commercial partnerships that are enhancing DefenCath's market penetration and adoption, thereby indicating strong revenue growth prospects. Additionally, by exploring new therapeutic indications such as Total Parenteral Nutrition and Oncology, Cormedix is solidifying its leadership position and demonstrating significant clinical benefits, further enhancing its value proposition in the healthcare sector.

Bears say

Cormedix Inc faces a negative outlook due to the high burden of catheter-related bloodstream infections (CRBSIs) associated with its target patient population, primarily those on total parenteral nutrition (TPN) and chronic dialysis. These infections lead to increased healthcare costs through prolonged hospital stays, additional medical interventions, and a deterioration in patient health and quality of life. The reliance of 15-20% of chronic dialysis patients on central venous catheters (CVCs) for extended periods further heightens the risk of complications, negatively impacting both patient outcomes and healthcare economics, ultimately presenting a substantial challenge for the company's product, DefenCath.

CorMedix (CRMD) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 11 analysts, CorMedix (CRMD) has a Buy consensus rating as of Jun 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.